Eli Lilly (Lilly) has agreee to acquire Centessa Pharmaceuticals in a deal worth up to $7.8bn. Centessa is a clinical-stage ...

Caregivers are vital to clinical trial retention, yet often overlooked—this article highlights their challenges, impact, and ...

Julie Kim, CEO-elect, is to be proposed as a candidate for the Board of Directors and Representative Director, President and ...

Biogen has agreed to acquire Apellis Pharmaceuticals for approximately $5.6bn.

Novo Nordisk’s Awiqli (insulin icodec) has been approved by the US FDA as the first and only once-weekly, long-acting basal ...

Sandoz has partnered with Samsung Bioepis to broaden patient access to high-quality biosimilar medicines worldwide. The ...

Novartis is to acquire Excellergy, a private biotech company developing next-generation anti-IgE therapies for IgE-driven ...

Gilead has agreed to acquire Tubulis, a private, clinical-stage biotechnology company focused on developing next-generation ...

Eli Lilly’s Foundayo (orforglipron), the only oral GLP-1 weight loss treatment that can be taken at any time of the day with no food or water restrictions, has been approved by ...

ReproNovo has appointed Mark Altmeyer as Chairman of the Board of Directors. Bringing over 35 years of experience to the role ...

Discover the story behind ‘The Site Factor’ and how understanding site teams’ experiences can transform clinical trials for ...